% | $
Quotes you view appear here for quick access.

Krispy Kreme Doughnuts, Inc. Message Board

letrob2000 26 posts  |  Last Activity: Feb 26, 2015 7:18 PM Member since: Jul 20, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Institutional Trading Alert for Johnson & Johnson

    Posted on 02/26/2015 by Edward Connelly

    A total of 22 block trades were executed today, typically at least 10,000 shares or more represent a single block unit. Block trades help investors understand the sentiment of large financial institutions. Further trading analysis reveals that 553.59K shares were bought and 224.81K shares were sold. The bought/sold ratio for shares of Johnson & Johnson is 2.46, representing a positive net cash flow of $33,681,888 into the stock.

    A deeper look into options trading also reveals that traders hedged their positions with options where 7.59K put and 22.29K call contracts exchanged hands leading to a 0.34 put/call ratio.
    Johnson & Johnson ranks as the world's largest and most diverse health-care company. The company comprises three divisions: pharmaceutical, medical devices and diagnostics, and consumer. While the pharmaceutical division currently represents close to 36% of total sales, we expect patent losses and the Synthes acquisition to reduce this proportion to approximately 27% during the next 10 years, with the device segment picking up the majority of the share.

    Johnson & Johnson settled the day up $1.59 to $102.80 in the previous trading session. Today's trading range was between $101.22 and $103.18 respectively. On the volume side, 11.18M shares were traded, which is greater than the average volume of 10.44M shares. JNJ is trading above the fifty day moving average and higher than the two hundred day moving average. The stock's 52 week low is $90.75 and 52 week high is $109.49. Within the last quarter, the shares have lost -5.51% of their value. The technical momentum Relative Strength Index indicator shows oversold conditions. The stock has a P/E ratio of 18.03 and a dividend yield of 0.70%.

    Sentiment: Strong Buy

  • letrob2000 letrob2000 Feb 26, 2015 7:12 PM Flag

    Outside the US, levosimendan is approved and marketed under the trade name of Simdax (levosimendan i.v.) in over 50 countries for use in Acute Decompensated Heart Failure. Over 800,000 patients have been prescribed the drug from its launch in early 2000.

    Mechanism of Action

    Levosimendan is a novel, first in class calcium sensitizer/K-ATP activator. The therapeutic effects of levosimendan are mediated through:
    •increased cardiac contractility by calcium sensitization of troponin C, resulting in a positive inotropic effect which is not associated with substantial increases in oxygen demand (3).
    •opening of potassium channels in the vasculature smooth muscle, resulting in a vasodilatory effect on all vascular beds (4).
    •opening of mitochondrial potassium channels in cardiomyocytes, resulting in a cardioprotective effect (5)

    Low Cardiac Output Syndrome:Definition and Incidence

    LCOS is generally defined as a patient’s inability to maintain a cardiac index 2.2 L/min/m2 and hence requiring use of inotropic agents and/or mechanical assist devices such as an intra aortic balloon pump or a left ventricular assistance device. LCOS in the cardiac surgery setting is reported to occur in 5-10% of patients undergoing cardiac surgery and is associated with 10-15 fold higher mortality or severe sequelae as a result of poor organ perfusion (eg. kidney failure, end stage renal disease [ESRD]) (6),(7),(8),(9) (10).

    Patient Outcomes

    Post-cardiotomy LCOS is associated with poor outcomes including a 10- to 15-fold increase in operative mortality (9).

    Unmet Medical Need

    Currently no pharmacologic therapies are approved for management or prevention of post-cardiotomy LCOS. While conventional inotropes are used to manage cardiac hemodynamics in the peri-operative setting, none have been shown to improve outcomes.

    Sentiment: Buy

  • Did the U.S. Goverment Just Ensure Success for Apple Inc Pay?

    By Daniel B. Kline | More Articles
    February 22, 2015 | Comments (0)

    The Obama administration has given Apple (NASDAQ: AAPL ) Pay the presidential seal of approval.

    The White House announced earlier this month that Apple Pay will join EMV chip-and-PIN as a standard for the roughly 9 million federal payment cards, including debit card accounts, used for distributing Social Security and veterans benefits. Apple Pay allows people to make financial transactions using credit or debit card information stored on an iPhone or iPad.

    A press release from the White House detailed the steps taken: "Apple, Visa, MasterCard, Comerica Bank, and U.S. Bank are committed to working together to make Apple Pay, a tokenized, encrypted service, available for users of federal payment cards, including DirectExpress and GSA SmartPay cards."

    Apple Pay will also be accepted starting in September for some government transactions, CEO Tim Cook said on Feb. 13th while speaking at the White House Summit on Cybersecurity and Consumer Protection.

    These moves put Apple Pay on increasingly equal footing with traditional payment methods and should help the product gain traction.

    What does this mean?
    Allowing use of Apple Pay in government payments opens up a huge pool of business for the company. It could also serve as a litmus test to whether the general public will embrace mobile payments.

    "Tech and financial industries are hoping mobile payments will be the next big thing, but consumers really haven't seemed too interested so far," said Newsy's Zach Toombs in a video posted at USA Today. "So, there will likely be a lot of focus as to whether people embrace Apple Pay through the federal government."

    Once the new option is launched, Apple Pay will be an option for people receiving Social Security, veterans benefits, and other government money in lieu of the current system of prepaid debit cards. The opportunity for Apple, wh

    Sentiment: Strong Buy

  • Reply to

    Will MAKO Still Report 3Q?

    by macnaughtonr Oct 25, 2013 1:49 PM
    letrob2000 letrob2000 Oct 25, 2013 9:37 PM Flag

    Earnings announcement is set for Nov 4. Click on Company Events just above Message Boards. Its listed there.

  • letrob2000 letrob2000 Oct 23, 2013 3:49 PM Flag

    Let's hope it happens after the first of the year.

    Sentiment: Hold

  • Reply to

    What's up in AH's

    by tomhaly76 Jul 8, 2013 5:51 PM
    letrob2000 letrob2000 Jul 8, 2013 5:59 PM Flag

    It might have to do with Intuitive Surgical missing their sales and cutting their guidance down $62.00.

  • Reply to


    by fisk007 Apr 12, 2013 11:40 AM
    letrob2000 letrob2000 Apr 19, 2013 11:28 AM Flag

    Sorry, wrong board.

  • Reply to


    by fisk007 Apr 12, 2013 11:40 AM
    letrob2000 letrob2000 Apr 19, 2013 11:27 AM Flag

    Sorry, wrong board.

  • Reply to


    by fisk007 Apr 12, 2013 11:40 AM
    letrob2000 letrob2000 Apr 18, 2013 2:21 PM Flag

    This stock never sold at $3. Never sold under $6.

  • Reply to

    New Article on MAKO in an ASC after one year

    by donknute Aug 9, 2012 4:30 PM
    letrob2000 letrob2000 Aug 10, 2012 5:44 PM Flag

    Yes, yes and yes

  • Reply to


    by bridgejumper08 Jul 27, 2012 10:25 AM
    letrob2000 letrob2000 Jul 27, 2012 11:54 AM Flag
  • Reply to

    Longs, watch your $$$$$$$ go bye bye bye bye

    by tonyroach967 Jul 11, 2012 4:41 PM
    letrob2000 letrob2000 Jul 11, 2012 4:50 PM Flag

    You are a true roach Tony.

  • Reply to

    KM & TK expect >$6 increase on mako tomorrow

    by t_hekid Mar 5, 2012 6:13 PM
    letrob2000 letrob2000 Mar 5, 2012 8:38 PM Flag

    I hope thier estimates are low and we top 50 Yaaaaa!!!!! Let's Go!! MAKO!!

  • Reply to

    Is this really the next ISRG?

    by to200andbeyond Feb 14, 2012 1:55 PM
    letrob2000 letrob2000 Feb 14, 2012 2:53 PM Flag

    Dr. Frederic Moll did NOT co-found MAKO. He is simply on the board of directors.

  • Reply to

    MAKO= 2 knees and 2 hips..ISRG= 1 prostate

    by beachdan1234 Jan 25, 2012 6:44 PM
    letrob2000 letrob2000 Jan 26, 2012 5:07 PM Flag

    8 times cause only men have prostates.

  • Reply to

    Like MAKO? Buy Hansen Medical (HNSN)

    by m_i_d_a_s_3_6_0 Jan 11, 2012 3:49 PM
    letrob2000 letrob2000 Jan 11, 2012 4:12 PM Flag

    That's not true. Get your facts straight!

  • letrob2000 letrob2000 Sep 19, 2011 6:18 PM Flag

    Mako gets a little Wall Street love by extending its robotic arms into total hip replacements

    September 19, 2011 by MassDevice staff

    Mako officially launches its robotic surgical system for use in total hip replacement procedures, winning a bump for share prices and a pat on the back from investment analysts.

    Mako Surgical Corp.'s (NSDQ:MAKO) commercial launch of the RIO surgical robotic arm for hip replacement surgery won some love from analysts and investors on Wall Street today.

    Shares jumped 7 percent to $38.76 in mid-day trading, after closing at $36.27 Friday, with analysts at Leerink Swann noting that MAKO shares are outperforming the market today.

    The device helps surgeons more accurately align and position implants based on a pre-operation three-dimensional model of the patient's hip. The robotic arm also assists the surgeon in preparing the joint and placing the hip implant.

    The device was cleared for use in February 2010, according to a press release, and has been available for surgical treatment of osteoarthritis of the knee for 5 years.

    "Mako's robotic hip solution has the potential to open up significant incremental revenue opportunities," wrote Leerink analysts Rick Wise and Richard Newitter. "The total hip arthroplasty market is much bigger than the market for partial knee replacements."

    "Mako's platform, until today, only targeted uni- and bi-compartmental knee procedures. We estimate the [worldwide] hip market represents a $5-6B opportunity," the analysts wrote.

    About 10 million Americans suffer from osteoarthritis of the hip, a wearing away of the cartilage that cushions the bones, causing pain and stiffness that can affect mobility. About half of the acetabular cups used in hip replacements are implanted improperly, which can lead to dislocation, fracture and increased wear on the implants, according to a study cited by Mako Surgical.

    The RIO system may have a tough battle ahead. Sunnyvale, Calif.-based Intuitive Surgical Inc. (NSDQ:ISRG), a Zacks Investment Research favorite, has virtually cornered the market on robotic surgery.

  • Reply to

    NOAH about to lose $10 For the last time...

    by michaelmcc123 Jun 17, 2011 11:13 AM
    letrob2000 letrob2000 Jun 17, 2011 1:42 PM Flag

    So why don't we short it and make a bundle?

  • Reply to

    I put in a stop

    by newyorknick25 May 31, 2011 11:57 AM
    letrob2000 letrob2000 May 31, 2011 12:34 PM Flag

    Precisely why I don't use stops. They are like hanging fruit for the MMs to get. They will drop the price just to steal your shares.

18.20+0.14(+0.78%)10:24 AMEDT